Reminder of Securities Fraud Lawsuit for Picard Medical Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy PMI?
Source: Businesswire
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a severe lack of confidence in the company's prospects.
- Fraudulent Promotion Exposed: Investigations revealed that Picard's stock was targeted by a fraudulent social media promotion scheme, where impersonators of financial advisors spread false information in online forums and social media to artificially inflate the stock price, exacerbating investor losses.
- Lawsuit Overview: The class action lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, leading investors to misunderstand the company's actual situation.
- Legal Action Deadline: Investors must file a motion by April 3, 2026, to request the court to appoint them as lead plaintiff if they meet specific legal requirements, ensuring their rights are protected in the ongoing lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Securities Fraud Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a severe lack of confidence in the company's prospects.
- Fraudulent Promotion Exposed: Investigations revealed that Picard's stock was targeted by a fraudulent social media promotion scheme, where impersonators of financial advisors spread false information in online forums and social media to artificially inflate the stock price, exacerbating investor losses.
- Lawsuit Overview: The class action lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, leading investors to misunderstand the company's actual situation.
- Legal Action Deadline: Investors must file a motion by April 3, 2026, to request the court to appoint them as lead plaintiff if they meet specific legal requirements, ensuring their rights are protected in the ongoing lawsuit.
See More
Faruqi & Faruqi Investigates Securities Claims Against Picard Medical
- Legal Claim Investigation: Faruq & Faruq LLP is investigating potential claims against Picard Medical, specifically targeting investors who purchased securities between September 2, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding the situation.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 3, 2026, making this timeline critical for affected investors.
- Company Background: Picard Medical (NYSE:PMI) is facing legal challenges, and the investigation by Faruq & Faruq LLP may impact its stock price and market confidence, prompting investors to closely monitor developments.
See More
Class Action Lawsuit Announced for Picard Medical, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Picard Medical securities between September 2 and October 31, 2025, alleging that the company made misleading statements that caused investor losses during this period.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any upfront costs, indicating that Rosen Law Firm operates on a contingency fee basis, which alleviates financial burdens for investors.
- Counsel Selection Importance: The firm emphasizes the importance of selecting qualified legal counsel, noting its track record of recovering over $438 million for investors in 2019 alone, showcasing its strength in securities class action litigation.
- Case Details Unveiled: The lawsuit alleges that Picard Medical failed to disclose critical information regarding its business and securities trading, including fraudulent stock promotions and insider trading, which misled investors about the company's prospects and could impact future stock performance.
See More
Securities Fraud Class Action Filed Against Picard Medical, Inc.
- Stock Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, closing at $3.99 from $13.20 per share, indicating a severe loss of investor confidence and significant financial repercussions for shareholders.
- Fraud Allegations: The lawsuit alleges that throughout the class period from September 2 to October 31, 2025, Picard failed to disclose that its stock was subject to a fraudulent social media promotion scheme, with insiders using offshore accounts to facilitate share dumping, misleading investors about the company's true financial health.
- Investor Rights: Affected investors have until April 3, 2026, to file a lead plaintiff motion to seek claims under federal securities laws, highlighting the legal framework aimed at protecting investor interests in the face of corporate misconduct.
- Legal Action Context: This lawsuit raises serious questions about the company's transparency and integrity, potentially leading to stricter regulatory scrutiny that could impact Picard's future financing capabilities and market reputation.
See More
Class Action Filed Against Picard Medical Following Stock Collapse
- Class Action Initiation: Scott+Scott Attorneys at Law has filed a class action lawsuit against Picard Medical and its executives, alleging manipulation of stock prices through false advertising between September and October 2025, resulting in significant investor losses.
- False Advertising Allegations: The lawsuit claims that the defendants failed to disclose material adverse facts about the company's operations and engaged in fraudulent social media promotions that artificially inflated Picard Medical's stock price, constituting a pump-and-dump scheme.
- Investor Losses: Affected investors who purchased Picard Medical securities between September 2 and October 31, 2025, are encouraged to contact attorneys for compensation, highlighting the severe impact of this incident on investor confidence.
- Legal Timeline: The lead plaintiff deadline for this class action is April 13, 2026, requiring investors to file with the court by this date to ensure their rights are protected in the lawsuit.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American: PMI) for violations of securities laws during the period from September 2, 2025, to October 31, 2025, urging affected investors to contact the firm before April 3, 2026, to participate in the lawsuit.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements, engaging in a manipulation scheme to fraudulently inflate its stock price, which resulted in significant losses for investors once the truth was revealed, highlighting serious compliance risks within the company.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help affected shareholders understand their rights and participate in the litigation.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to take action may remain absent class members, potentially forfeiting their claims.
See More
Reminder of Securities Fraud Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a severe lack of confidence in the company's prospects.
- Fraudulent Promotion Exposed: Investigations revealed that Picard's stock was targeted by a fraudulent social media promotion scheme, where impersonators of financial advisors spread false information in online forums and social media to artificially inflate the stock price, exacerbating investor losses.
- Lawsuit Overview: The class action lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, leading investors to misunderstand the company's actual situation.
- Legal Action Deadline: Investors must file a motion by April 3, 2026, to request the court to appoint them as lead plaintiff if they meet specific legal requirements, ensuring their rights are protected in the ongoing lawsuit.
See More
Faruqi & Faruqi Investigates Securities Claims Against Picard Medical
- Legal Claim Investigation: Faruq & Faruq LLP is investigating potential claims against Picard Medical, specifically targeting investors who purchased securities between September 2, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding the situation.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 3, 2026, making this timeline critical for affected investors.
- Company Background: Picard Medical (NYSE:PMI) is facing legal challenges, and the investigation by Faruq & Faruq LLP may impact its stock price and market confidence, prompting investors to closely monitor developments.
See More
Class Action Lawsuit Announced for Picard Medical, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Picard Medical securities between September 2 and October 31, 2025, alleging that the company made misleading statements that caused investor losses during this period.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any upfront costs, indicating that Rosen Law Firm operates on a contingency fee basis, which alleviates financial burdens for investors.
- Counsel Selection Importance: The firm emphasizes the importance of selecting qualified legal counsel, noting its track record of recovering over $438 million for investors in 2019 alone, showcasing its strength in securities class action litigation.
- Case Details Unveiled: The lawsuit alleges that Picard Medical failed to disclose critical information regarding its business and securities trading, including fraudulent stock promotions and insider trading, which misled investors about the company's prospects and could impact future stock performance.
See More
Securities Fraud Class Action Filed Against Picard Medical, Inc.
- Stock Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, closing at $3.99 from $13.20 per share, indicating a severe loss of investor confidence and significant financial repercussions for shareholders.
- Fraud Allegations: The lawsuit alleges that throughout the class period from September 2 to October 31, 2025, Picard failed to disclose that its stock was subject to a fraudulent social media promotion scheme, with insiders using offshore accounts to facilitate share dumping, misleading investors about the company's true financial health.
- Investor Rights: Affected investors have until April 3, 2026, to file a lead plaintiff motion to seek claims under federal securities laws, highlighting the legal framework aimed at protecting investor interests in the face of corporate misconduct.
- Legal Action Context: This lawsuit raises serious questions about the company's transparency and integrity, potentially leading to stricter regulatory scrutiny that could impact Picard's future financing capabilities and market reputation.
See More
Class Action Filed Against Picard Medical Following Stock Collapse
- Class Action Initiation: Scott+Scott Attorneys at Law has filed a class action lawsuit against Picard Medical and its executives, alleging manipulation of stock prices through false advertising between September and October 2025, resulting in significant investor losses.
- False Advertising Allegations: The lawsuit claims that the defendants failed to disclose material adverse facts about the company's operations and engaged in fraudulent social media promotions that artificially inflated Picard Medical's stock price, constituting a pump-and-dump scheme.
- Investor Losses: Affected investors who purchased Picard Medical securities between September 2 and October 31, 2025, are encouraged to contact attorneys for compensation, highlighting the severe impact of this incident on investor confidence.
- Legal Timeline: The lead plaintiff deadline for this class action is April 13, 2026, requiring investors to file with the court by this date to ensure their rights are protected in the lawsuit.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American: PMI) for violations of securities laws during the period from September 2, 2025, to October 31, 2025, urging affected investors to contact the firm before April 3, 2026, to participate in the lawsuit.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements, engaging in a manipulation scheme to fraudulently inflate its stock price, which resulted in significant losses for investors once the truth was revealed, highlighting serious compliance risks within the company.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help affected shareholders understand their rights and participate in the litigation.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to take action may remain absent class members, potentially forfeiting their claims.
See More
